Aura Biosciences completes CoMpass treatment visits, confirms 2H 2027 data timing
All 108 participants in the Phase 3 trial of bel-sar have finished treatment, with topline data still expected in the second half of 2027.
SEC filing
1 story
All 108 participants in the Phase 3 trial of bel-sar have finished treatment, with topline data still expected in the second half of 2027.
SEC filing